ShareSpot
-
Recap: 17th Ryan White HIV/AIDS Program Clinical Care Conference
Highlights from Laura W. Cheever, MD, ScM, HRSA HIV/AIDS Bureau Associate Administrator and Conference Co-Chair
The field of HIV/AIDS care and treatment continues to evolve rapidly. Groundbreaking developments in HIV research are regularly presented at international meetings and...
-
Evolving: A Journey in Practice Transformation
I remember driving to Chicago on my first day as a Midwest AETC Practice Transformation (PT) Coach filled with both excitement and apprehension to participate in a 3-day intensive training titled Building Blocks of High Performing Primary Care. While the concepts of PT were familiar to me after...
-
CROI 2017: Doravirine Noninferior to Darunavir + Ritonavir in Initial Treatment
Doravirine is an investigational NNRTI that is active in vitro against many common NNRTI resistance mutations (including K103N, Y181C, and E138K). It is given once daily, has no food restrictions, and can be given with acid-blocking medications. In a Phase 2 study of treatment-...
-
CROI 2017: Bictegravir and Dolutegravir, Head-to-Head Comparison
Bictegravir is an investigational integrase inhibitor that is dosed once daily, unboosted. It is active in vitro against many viruses with integrase resistance mutations. A Phase 2 double-blind placebo-controlled study randomized treatment-naive patients (n...
-
CROI 2017: Dolutegravir in 2-Drug Simplification Studies
In recent years, a number of studies have evaluated 2-drug or even 1-drug ARV regimens, either in initial therapy or in switch regimens for patients with virologic suppression on 3-drug therapy. In general, these have not been as successful in achieving or maintaining virologic suppression as...
-
CROI 2017: Failure of Dolutegravir Monotherapy
Leading up to this year, some researchers and clinicians had optimistically viewed dolutegravir an invincible ARV, a drug so mighty that it was unlikely to fail, and even more unlikely to be victim to emergent resistance mutations. Two presentations at CROI demonstrated the...
-
Tuesday Morning HIV Discussion Series: South Central AETC collaborates with the University of Texas Southwestern Medical Center
In February 2016 Elyse Malanowski, MLS, became the Education Coordinator for Parkland Health and Hospital System/North Texas for the South Central AETC (SCAETC). The SCAETC along with the University of Texas Southwestern (UTSW) Medical Center co-host a weekly informational session for clinicians...
-
Journal Articles by AETC-Affiliated Researchers and Faculty--2016
It's been a busy year for the AETC community, and we are proud to present the following compilation of published studies produced by members of our network during the 2016 calendar year. Also included is the HRSA/HAB Workforce Survey results published in the AAHIVM HIV Specialist. AETC-...
-
Join HAB and NQC in the end+disparities Learning Exchange
The National Quality Center (NQC) and HIV/AIDS Bureau (HAB) are pleased to announce the end+disparities Learning Exchange! Please watch the informational video and share it with your colleagues and social media contacts!
The 9-month initiative is open to all Ryan White HIV/AIDS Program (...
-
Addiction Recovery and HIV: Finding Synergy
When we talk about HIV and drug addiction, we most often focus on injection drug use (IDU) as a risk factor for HIV transmission. While only 2.6% of the country’s population over the age of 13 reports having injected drugs at some point during their lives1, approximately 10% of new HIV...
-
HIV Meds Update: ART in Acute HIV--Decreasing HIV DNA
We know that very early treatment in acute HIV infection decreases HIV RNA; this study shows it also greatly decreases proviral DNA (and reservoir size). Researchers investigated 2 small cohorts of patients in Thailand with acute (and very early) HIV infection, 1 untreated and 1 treated with ART...
-
HIV Meds Update: Improvements in ART and Viral Suppression Rates in the United States
Using data from the Medical Monitoring Project, this article presents a useful view of ARV treatment in the United States. The analysis demonstrates that U.S. national rates of both ARV prescribing (for persons maintained in care) and viral suppression to <200 copies/mL increased from...
-
HIV Meds Update: PrEP Uptake by Sex, Race, and Age
At the ASM Microbe meeting in June, researchers from Gilead Sciences presented data on use of TDF/FTC (Truvada) PrEP in the United States according to sex and race. They evaluated national pharmacy databases to identify prescriptions of TDF/FTC given for PrEP between January 2012 and September...
-
HIV Meds Update - RAPID: Immediate ART Initiation
This publication presents the results of San Francisco General Hospital's Ward 86 pilot study of immediate ART initiation. This RAPID program systematically offered ART to patients upon diagnosis of HIV; patients were referred from HIV testing sites in San Francisco. Of the 39 patients who...
-
HIV Meds Update: Treatment as Prevention: Suppressive ART, Condomless Sex, and HIV Transmission Risk; also a Word on HPTN 052
The PARTNER Study, a multisite European study, evaluated rates of HIV transmissions within serodifferent heterosexual and MSM couples (n = 548 and n = 340, respectively, contributed eligible data). The HIV-positive partners were on ART with HIV RNA levels of <200 copies/mL, and the couples...
-
HIV Meds Update: HIV in Indiana
This article describes the CDC investigation and response (through October 2015) to the ongoing HIV (and HCV) outbreak in a rural county in Indiana, centered in people who inject opiates (especially the prescription drug Opana [oxymorphone]). The outbreak was first recognized in...
-
HIV and Heart Disease – NIH Explores the Connection
HIV-positive men and women can now live longer than ever before. A 2013 study found that a newly diagnosed 20-year-old on effective antiretroviral therapy (ART) can expect to live into their 70s, a lifespan only slightly lower than in people without HIV.[1] While this is great news, physicians...
-
Accessibility: The Bigger Picture
I have been working on website accessibility for many years in my role as Production Manager at the UCSF Center for HIV Information. Despite that experience, I still encounter problems that confound me. I recently reached out to an accessibility expert for ideas on how to manage a particularly...
-
Use of Dolutegravir in Dialysis
Dolutegravir has several characteristics that, in theory, suggest it will not be significantly removed by dialysis: It has a large apparent volume of distribution (17.4 L) and is highly protein bound (98.9%). A small study of 5 HIV-infected patients with end-stage renal disease undergoing...
-
PrEP: Bone Density Improves after Stopping TDF/FTC
Tenofovir disoproxil fumarate (TDF) may cause decreases in bone mineral density (BMD) both in HIV-infected patients treated with TDF-containing ARV regimens and in HIV-uninfected persons who use it for PrEP. A substudy of the large iPrEx trial of TDF/FTC PrEP in MSM and transgender...
Search ShareSpot
User login
Suggest a Blog Topic
Is there a topic you'd like us to discuss here? Let us know!